Physician profile
Leny Abraham
NPI 1114314283
$1,905.23
in general payments reported to CMS, 2019-2025
14 companies · $1,905 in 2025
The $1,905 reported for 2025 was more than what 85% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $1,905.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,905.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,905.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $291.15 | 2025 | Biktarvy |
| Viiv Healthcare Company | $281.46 | 2025 | Dovato, Cabenuva, Apretude |
| Merck Sharp & Dohme LLC | $212.09 | 2025 | Pifeltro, Zerbaxa, Capvaxive |
| Insmed, INC. | $207.80 | 2025 | Arikayce, Brinsupri |
| Aimmune Therapeutics, INC. | $203.37 | 2025 | Vowst, Zenpep |
| Melinta Therapeutics, LLC | $141.37 | 2025 | Rezzayo, Kimyrsa, Orbactiv |
| Paratek Pharmaceuticals, INC. | $139.80 | 2025 | Nuzyra |
| Abbvie INC. | $98.82 | 2025 | |
| Ferring Pharmaceuticals INC. | $83.22 | 2025 | Rebyota |
| Theratechnologies INC. | $72.75 | 2025 | Trogarzo, Egrifta |
| Shionogi INC | $61.55 | 2025 | Fetroja |
| La Jolla Pharmaceutical Company | $44.63 | 2025 | Zevtera |
| Cumberland Pharmaceuticals, INC. | $41.11 | 2025 | Vibativ |
| Seqirus USA INC | $26.11 | 2025 | Flucelvax, Fluad |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leny Abraham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.